A Review of China’s Life Science and Healthcare Sector 2021: Embracing a Dynamic Regulatory Landscape

Jan 9, 2022
Ting Wu of Haiwen & Partners reviews the regulatory reforms taking place in China’s life science and healthcare sector including legislation that has been released to encourage innovation and broaden market access to drugs, implementation of the patent linkage system, increasing antitrust enforcement pressure in the pharma sector, regulating medical devices, cosmetics and online hospitals.

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
 

 

Summary


This premium content is reserved for
China Law & Practice Subscribers.

A Premium Subscription Provides:

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment

Subscribe Now

For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].